LONP1-IN-2
Based on 3 publication(s) in Google Scholar
LONP1-IN-2 (Compound 9e) is a potent and selective LONP1 inhibitor with an IC50 value of 0.093 μM. LONP1-IN-2 can be used in research of cancer.
For research use only. We do not sell to patients.
- Purity: 99.43%
- CAS No.: 2729981-17-1
- Formula: C16H27BN4O4
- Molecular Weight:350.22
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Covalent Screening Library
HY-L036
-
Ubiquitination Compound Library
HY-L050
-
Anti-Blood Cancer Compound Library
HY-L079
-
Metabolic Enzyme Compound Library
HY-L146
-
Protease Inhibitor Library
HY-L147
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Boronic Acid Compound Library
HY-L167
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) LONP1-IN-2
More
Customer Validation & Images
-
WB
-
WB
-
Cell Proliferation/Viability Assay
-
IF
Biological Activity
LONP1-IN-2 (0.5 μM; 2-6 h) increases the levels of PTPMT1 and GOT2 in GM12878 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:GM12878 cells
-
Concentration:0.5 μM
-
Incubation Time:2, 4 and 6 h
-
Result:Increased the levels of PTPMT1 and GOT2.
Chemical Information
-
CAS No. 2729981-17-1
-
Appearance Solid
-
Molecular Weight 350.22
-
Formula C16H27BN4O4
-
Color White to off-white
-
SMILES
CC(C)C[C@@H](B(O)O)NC([C@@H](CCCC)NC(C1=NC=CN=C1)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Sci Adv
Epstein-Barr virus-driven cardiolipin synthesis sustains metabolic remodeling during B cell transformation. [Abstract]2025 Jan 31;11(5):eadr8837. PMID: 39879311
LONP1-IN-2 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Jan 31;11(5):eadr8837. [Abstract]
Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 treated with DMSO or 0.5 μM LONP1-in-2 for indicated time.
LONP1-IN-2 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Jan 31;11(5):eadr8837. [Abstract]
Immunoblot analysis for PTPMT1, GOT2, and actin in WCL of GM12878 LCL expressing control or PTPMT1 sgRNAs, treated with DMSO or 0.5 μM LONP1-in-2 for 24 hours.
-
Pharm Biol
Wen-Shen-Tong-Luo-Zhi-Tong Decoction alleviates bone loss in aged mice by suppressing LONP1-mediated macrophage senescence. [Abstract]2025 Dec;63(1):524-548. PMID: 40719285
LONP1-IN-2 purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2025 Dec;63(1):524-548. [Abstract]
The CCK-8 assay was employed to assess the viability of RAW264.7 cells and H2O2-induced senescent RAW264.7 cells, both subjected to treatment with the LONP1 inhibitor, LONP1-IN-2.
LONP1-IN-2 purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2025 Dec;63(1):524-548. [Abstract]
Immunofluorescence staining of cGAS and STING in BMSCs treated with RAW-CM in each group. (The cells were subjected to treatment with the LONP1 inhibitor, LONP1-IN-2.)
-
Solvent & Solubility
DMSO : 100 mg/mL (285.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (7.14 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (7.14 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5.95 mg/mL (16.99 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kingsley LJ, et, al. Structure-Based Design of Selective LONP1 Inhibitors for Probing In Vitro Biology. J Med Chem. 2021 Apr 22;64(8):4857-4869. [Content Brief]
[2]. You H, et al. Epstein-Barr virus-driven cardiolipin synthesis sustains metabolic remodeling during B cell transformation. Sci Adv. 2025 Jan 31;11(5):eadr8837. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8553 mL | 14.2767 mL | 28.5535 mL | 71.3837 mL |
| 5 mM | 0.5711 mL | 2.8553 mL | 5.7107 mL | 14.2767 mL | |
| 10 mM | 0.2855 mL | 1.4277 mL | 2.8553 mL | 7.1384 mL | |
| 15 mM | 0.1904 mL | 0.9518 mL | 1.9036 mL | 4.7589 mL | |
| 20 mM | 0.1428 mL | 0.7138 mL | 1.4277 mL | 3.5692 mL | |
| 25 mM | 0.1142 mL | 0.5711 mL | 1.1421 mL | 2.8553 mL | |
| 30 mM | 0.0952 mL | 0.4759 mL | 0.9518 mL | 2.3795 mL | |
| 40 mM | 0.0714 mL | 0.3569 mL | 0.7138 mL | 1.7846 mL | |
| 50 mM | 0.0571 mL | 0.2855 mL | 0.5711 mL | 1.4277 mL | |
| 60 mM | 0.0476 mL | 0.2379 mL | 0.4759 mL | 1.1897 mL | |
| 80 mM | 0.0357 mL | 0.1785 mL | 0.3569 mL | 0.8923 mL | |
| 100 mM | 0.0286 mL | 0.1428 mL | 0.2855 mL | 0.7138 mL |
Powered by Bioz